Cotan Horia, Iaciu Cristian, Nitipir Cornelia
Oncology, Elias Emergency University Hospital, Bucharest, ROU.
Clinic of Oncology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Cureus. 2024 Jul 19;16(7):e64916. doi: 10.7759/cureus.64916. eCollection 2024 Jul.
Background This study aims to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in patients with metastatic colorectal cancer (mCRC). Methodology A retrospective analysis was conducted among 65 patients diagnosed with stage IV colorectal cancer who received treatment and follow-up at the Oncology Department of Elias Emergency University Hospital in Bucharest, Romania, from January 2016 to January 2024. Patient data were collected, including demographic information, tumor characteristics, and laboratory parameters. The mGPS was calculated based on serum albumin and C-reactive protein (CRP) levels. Patients were stratified into the following three mGPS categories: 0 (normal CRP and albumin), 1 (elevated CRP or hypoalbuminemia), and 2 (elevated CRP and hypoalbuminemia). Results Of the 65 patients included, 33 (50.8%) were male and 32 (49.2%) were female, with a mean age of 63.7 years. According to mGPS, 25 (38.5%) patients scored 0, 30 (46.2%) scored 1, and 10 (15.4%) scored 2. The median overall survival (OS) was 53 months (95% confidence interval (CI) = 23.512-82.488), and the median progression-free survival (PFS) was 23 months (95% CI = 19.244-26.756). Although numerical differences in the median PFS and OS were observed between treatment groups, these differences were not statistically significant (PFS: p = 0.292; OS: p = 0.5). Conclusions The mGPS is a useful prognostic tool in mCRC, providing insights into patient survival outcomes. However, further studies with larger sample sizes are needed to validate these findings and clarify the role of mGPS in guiding clinical decision-making for mCRC patients.
背景 本研究旨在评估改良格拉斯哥预后评分（mGPS）在转移性结直肠癌（mCRC）患者中的预后意义。方法 对2016年1月至2024年1月在罗马尼亚布加勒斯特埃利亚斯急诊大学医院肿瘤科接受治疗和随访的65例诊断为IV期结直肠癌的患者进行回顾性分析。收集患者数据，包括人口统计学信息、肿瘤特征和实验室参数。根据血清白蛋白和C反应蛋白（CRP）水平计算mGPS。患者被分为以下三个mGPS类别：0（CRP和白蛋白正常）、1（CRP升高或低白蛋白血症）和2（CRP升高且低白蛋白血症）。结果 纳入的65例患者中，33例（50.8%）为男性，32例（49.2%）为女性，平均年龄63.7岁。根据mGPS，25例（38.5%）患者评分为0，30例（46.2%）评分为1，10例（15.4%）评分为2。中位总生存期（OS）为53个月（95%置信区间（CI）=23.512 - 82.488），中位无进展生存期（PFS）为23个月（95%CI = 19.244 - 26.756）。虽然在治疗组之间观察到中位PFS和OS存在数值差异，但这些差异无统计学意义（PFS：p = 0.292；OS：p = 0.5）。结论 mGPS是mCRC中一种有用的预后工具，可提供患者生存结果的相关信息。然而，需要更大样本量的进一步研究来验证这些发现，并阐明mGPS在指导mCRC患者临床决策中的作用。
